Article Information
History
- December 8, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Dalin Li, PhD1,
- Alexander Xu, PhD2,
- Emebet Mengesha, BS1,
- Rebecca Elyanow, PhD3,
- Rachel M. Gittelman, PhD3,
- Heidi Chapman, PhD3,
- John C. Prostko, MS4,
- Edwin C. Frias, MBA4,
- James L. Stewart, PhD4,
- Valeriya Pozdnyakova, BS1,
- Philip Debbas, BS1,
- Angela Mujukian, M.D.1,
- Arash A Horizon, MD5,
- Noah Merin, MD, PhD2,
- Sandy Joung, MHDS6,
- Gregory J. Botwin, BS1,
- Kimia Sobhani, PhD7,
- Jane C. Figueiredo, PhD2,
- Susan Cheng, MD, MMSc, MPH6,
- Ian M. Kaplan, PhD3,
- Dermot P.B. McGovern, MB BS, D Phil1,
- Akil Merchant, MD2,
- Gil Y. Melmed, MD, MS1 and
- Jonathan Braun, MD, PhD1,7,*
- 1F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA
- 2Cedars Sinai Cancer and Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA
- 3Adaptive Biotechnologies, Seattle, WA, USA
- 4Applied Research and Technology, Abbott Diagnostics, Abbott Park, IL
- 5Center for Rheumatology Medical Group, Los Angeles, CA, USA
- 6Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA
- 7Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA
- ↵*Contact information
Jonathan Braun, MD, PhD, Inflammatory Bowel and Immunobiology Research Institute, Karsh Division of Digestive and Liver Diseases, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, 310-423-8717, jonathan.braun2{at}cshs.org
Posted December 08, 2021.
The T-cell clonal response to SARS-CoV-2 vaccination in inflammatory bowel disease patients is augmented by anti-TNF therapy and often deficient in antibody-responders
